MedTrace Logo

Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss

NCT02038972 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-03-05

No results posted yet for this study

Summary

To determine if autologous human umbilical cord blood infusion in children with acquired hearing loss is safe, feasible, improves inner ear function, audition and language development.

Conditions

  • Sensorineural Hearing Loss

Interventions

GENETIC

Autologous Stem Cells

The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.

Sponsors & Collaborators

  • CBR Systems, Inc.

    collaborator OTHER

  • James Baumgartner, MD

    lead OTHER

Principal Investigators

  • James Baumgartner, MD · AdventHealth

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Weeks
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-12-11
Completion
2017-01-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02038972 on ClinicalTrials.gov